NO964073D0 - Diagnose og terapi samt cellulære og dyremodeller for sykdommer assosiert med mitokondriske defekter - Google Patents

Diagnose og terapi samt cellulære og dyremodeller for sykdommer assosiert med mitokondriske defekter

Info

Publication number
NO964073D0
NO964073D0 NO964073A NO964073A NO964073D0 NO 964073 D0 NO964073 D0 NO 964073D0 NO 964073 A NO964073 A NO 964073A NO 964073 A NO964073 A NO 964073A NO 964073 D0 NO964073 D0 NO 964073D0
Authority
NO
Norway
Prior art keywords
diagnosis
therapy
cellular
well
animal models
Prior art date
Application number
NO964073A
Other languages
English (en)
Other versions
NO964073L (no
Inventor
Corinna Herrnstadt
William Davis Parker
Robert E Davis
Scott Wiliam Miller
Original Assignee
Mitokor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/219,842 external-priority patent/US5565323A/en
Priority claimed from US08/397,808 external-priority patent/US5888498A/en
Application filed by Mitokor filed Critical Mitokor
Publication of NO964073D0 publication Critical patent/NO964073D0/no
Publication of NO964073L publication Critical patent/NO964073L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0053—Oxidoreductases (1.) acting on a heme group of donors (1.9)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
NO964073A 1994-03-30 1996-09-27 Diagnose og terapi samt cellulære og dyremodeller for sykdommer assosiert med mitokondriske defekter NO964073L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/219,842 US5565323A (en) 1994-03-30 1994-03-30 Cytochrome oxidase mutations aiding diagnosis of sporadic alzheimer's disease
US08/397,808 US5888498A (en) 1995-03-03 1995-03-03 Cellular and animal models for diseases associated with mitochondrial defects
PCT/US1995/004063 WO1995026973A1 (en) 1994-03-30 1995-03-30 Diagnosis, therapy and cellular and animal models for diseases associated with mitochondrial defects

Publications (2)

Publication Number Publication Date
NO964073D0 true NO964073D0 (no) 1996-09-27
NO964073L NO964073L (no) 1996-11-29

Family

ID=26914309

Family Applications (1)

Application Number Title Priority Date Filing Date
NO964073A NO964073L (no) 1994-03-30 1996-09-27 Diagnose og terapi samt cellulære og dyremodeller for sykdommer assosiert med mitokondriske defekter

Country Status (12)

Country Link
US (1) US20010021526A1 (no)
EP (1) EP0751951A4 (no)
JP (1) JPH09511398A (no)
CN (1) CN1150433A (no)
AU (1) AU705230B2 (no)
BR (1) BR9507241A (no)
CA (1) CA2186636A1 (no)
FI (1) FI963884A7 (no)
MX (1) MX9604400A (no)
NO (1) NO964073L (no)
NZ (1) NZ283660A (no)
WO (1) WO1995026973A1 (no)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6027880A (en) 1995-08-02 2000-02-22 Affymetrix, Inc. Arrays of nucleic acid probes and methods of using the same for detecting cystic fibrosis
US7115364B1 (en) 1993-10-26 2006-10-03 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US6309823B1 (en) 1993-10-26 2001-10-30 Affymetrix, Inc. Arrays of nucleic acid probes for analyzing biotransformation genes and methods of using the same
US20060229824A1 (en) 1993-10-26 2006-10-12 Affymetrix, Inc. Arrays of nucleic acid probes for analyzing biotransformation genes
US5840493A (en) * 1994-03-30 1998-11-24 Mitokor Mitochondrial DNA mutations that segregate with late onset diabetes mellitus
US6291172B1 (en) * 1995-03-03 2001-09-18 Mitokor Diagnostic assay for diabetes mellitus based on mutational burden
WO1996030545A1 (en) * 1995-03-24 1996-10-03 Mitokor Mutation detection by differential primer extension of mutant and wildtype target sequences
US6391550B1 (en) 1996-09-19 2002-05-21 Affymetrix, Inc. Identification of molecular sequence signatures and methods involving the same
GB9620028D0 (en) * 1996-09-26 1996-11-13 Ludwig Inst Cancer Res Factors which interact with oncoproteins
US20020106354A1 (en) * 1998-04-28 2002-08-08 Christen M. Anderson Cellular and animal models for diseases associated with altered mitochondrial function
US6489095B2 (en) 1998-06-15 2002-12-03 Mitokor Diagnostic method based on quantification of extramitochondrial DNA
US6441149B1 (en) * 1998-06-15 2002-08-27 Mitokor Diagnostic method based on quantification of extramitochondrial DNA
NZ513926A (en) * 1999-02-23 2001-09-28 Univ California Methods of treatment of mitochondrial disorders
WO2000055323A1 (en) * 1999-03-16 2000-09-21 Mitokor Differential expression of organellar gene products
FR2798556B1 (fr) * 1999-09-17 2004-02-27 Aventis Pharma Sa Nouveau modele animal de la maladie d'alzheimer presentant a la fois des plaques amyloides et des dysfonctionnements mitochondriaux
JP2003509071A (ja) * 1999-09-17 2003-03-11 アバンテイス・フアルマ・エス・アー アミロイド斑およびミトコンドリア機能障害を示すアルツハイマー病の新規の動物モデル
CN1277995A (zh) * 1999-11-22 2000-12-27 上海博容基因开发有限公司 一种新的多肽——人细胞色素氧化酶相关蛋白37和编码这种多肽的多核苷酸
CN1322143C (zh) * 2000-12-04 2007-06-20 普里马根公司 检测线粒体核酸与核基因核酸比率确定药物活性和/或副作用的方法
JP2003116576A (ja) * 2001-10-17 2003-04-22 Gifu International Institute Of Biotechnology ヒトミトコンドリアｄｎａを用いた遺伝子検出方法
CN1839142B (zh) 2003-08-22 2010-06-16 澳新制药公司 用作靶向线粒体的抗氧化剂的线粒体醌衍生物
US7888334B2 (en) 2003-08-22 2011-02-15 Antipodean Pharmaceuticals, Inc. Mitoquinone derivatives used as mitochondrially targeted antioxidants
CN101137735A (zh) * 2005-03-09 2008-03-05 西菲伊德公司 极性染料
EP2150117A4 (en) * 2007-05-02 2011-10-05 Mclean Hospital Corp METHODS AND COMPOSITIONS FOR MITOCHONDRIA REPLACEMENT THERAPY
IL282198B2 (en) 2011-09-11 2025-11-01 Minovia Therapeutics Ltd Compositions of functional mitochondria and uses thereof
EP2904391B1 (en) * 2012-10-05 2018-01-17 Neurovive Pharmaceutical AB Mitochondrial toxicity test
KR101556439B1 (ko) 2013-07-01 2015-10-15 서울대학교산학협력단 미토콘드리아 역행성 신호 경로와 관련된 ＲＸＲα의 기능 및 용도
ES3052812T3 (en) 2017-05-08 2026-01-14 Flagship Pioneering Innovations V Inc Compositions for facilitating membrane fusion and uses thereof
CN107746889A (zh) * 2017-07-17 2018-03-02 国家海洋局北海环境监测中心 用于扩增底栖多毛类环节动物线粒体co i基因片段的引物
EP3823640A4 (en) 2018-07-22 2022-05-18 Minovia Therapeutics Ltd. MITOCHONDRIAL AUGMENTATION THERAPY OF MUSCULAR DISEASES
JP7522095B2 (ja) 2018-07-22 2024-07-24 ミノヴィア セラピューティクス リミテッド 原発性ミトコンドリア病のためのミトコンドリア増強療法
ES2992862T3 (en) 2018-07-22 2024-12-18 Minovia Therapeutics Ltd Mitochondrial augmentation therapy of renal diseases
WO2020021538A1 (en) 2018-07-22 2020-01-30 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of brain diseases
WO2020021540A1 (en) 2018-07-22 2020-01-30 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of pancreatic diseases
US12239672B2 (en) 2018-07-22 2025-03-04 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of ocular diseases
US12268714B2 (en) 2018-09-14 2025-04-08 Luca Science Inc. Transplantation of mitochondria into lymphoid organ and composition therefor
CN109796527B (zh) * 2019-03-07 2020-09-04 广西大学 一种红麻线粒体蛋白cox3抗原多肽及制备多克隆抗体的方法和应用
CN111034736B (zh) * 2019-12-13 2021-04-06 西北农林科技大学 一种杀虫组合物及其应用
EP4125948A4 (en) 2020-03-31 2024-05-29 Minovia Therapeutics Ltd. Mitochondria-enriched genetically engineered cells and uses thereof
CN111579763B (zh) * 2020-04-09 2023-04-07 北京博瑞世安科技有限公司 检测白细胞线粒体呼吸功能的方法及检测肾阴虚症的方法
CN111781175B (zh) * 2020-06-18 2023-04-21 中国人民解放军军事科学院国防科技创新研究院 一种用于提高细胞中线粒体活性的方法及装置和应用
WO2024015951A2 (en) * 2022-07-15 2024-01-18 Seq Biomarque, Llc Methods and materials for identifying biomarkers and/or pathways associated with alzheimer's disease
CN115960087B (zh) * 2022-09-16 2024-06-07 浙江工业大学 黏度响应型双光子荧光化合物及其合成与应用
CN117384269B (zh) * 2023-09-21 2024-06-18 南方医科大学南方医院 短肽mfrlp及其在制备动脉重塑相关疾病药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185244A (en) * 1989-12-08 1993-02-09 Emory University Genetic test for hereditary neuromuscular disease
US5296349A (en) * 1990-06-14 1994-03-22 Emory University Molecular genetic test for myoclonic epilepsy
US5494794A (en) * 1992-10-20 1996-02-27 Emory University Detection of mitochondrial DNA mutations associated with Alzheimer's disease and Parkinson's disease
US5506101A (en) * 1993-06-30 1996-04-09 Cedars-Sinai Medical Center Method for detection of susceptibility mutations for ototoxic deafness

Also Published As

Publication number Publication date
CN1150433A (zh) 1997-05-21
JPH09511398A (ja) 1997-11-18
FI963884A0 (fi) 1996-09-27
WO1995026973A1 (en) 1995-10-12
EP0751951A1 (en) 1997-01-08
NZ283660A (en) 1998-07-28
MX9604400A (es) 1997-12-31
CA2186636A1 (en) 1995-10-12
NO964073L (no) 1996-11-29
AU705230B2 (en) 1999-05-20
FI963884A7 (fi) 1996-11-26
BR9507241A (pt) 1997-09-16
EP0751951A4 (en) 2000-05-03
AU2204295A (en) 1995-10-23
US20010021526A1 (en) 2001-09-13

Similar Documents

Publication Publication Date Title
FI963884A7 (fi) Diagnoosi, hoito ja solu- ja eläinmallit tauteja varten, joihin liittyy mitokondriodefektejä
BG95935A (bg) Метод и средство за приемане на дексмедетомидин директно през кожата
DE69504591D1 (de) Ophthalmologisches Gerät für Fundusbilderzeugung
DE69406126D1 (de) Schutzvorrichtung für den menschlichen körper
ATE238073T1 (de) Verbesserungen für oder in bezug auf kontrastmitteln in ultraschallbilddarstellung
DE69123751D1 (de) Stall für tiere
DE68928578D1 (de) Ultraschallvorrichtung für therapeutischen Gebrauch
ATE139550T1 (de) Reversion verhindernde mittel in kautschukvulkanisation
DE69033150D1 (de) Tierstreu und Verfahren
DE69129774D1 (de) Vorrichtung für Ultraschallmessungen in Bohrlöchern
FI953854A0 (fi) Sydämen tarkkailu- ja diagnoosimenetelmä
FI943625A7 (fi) Menetelmiä tulehduksellisten ihotautien hoitamiseksi
NO885367D0 (no) Hudrense- og -kondisjoneringsmiddel.
DE69309727D1 (de) Vorrichtung zum Nachweisen okkulten Blutes in den Fäkalien
DE3852985D1 (de) Ophthalmisches Ultraschall-Messgerät.
MX7575A (es) Agentes de vulcanizacion de caucho y metodos para su preparacion.
IL91703A0 (en) Animal model for diagnosing therapeutic agents against aids
FI912236A7 (fi) Laite teuraseläimen peräsuolen irrottamiseksi
PT764157E (pt) Benzopiranos e sua utilizacao como agentes terapeuticos
DE69304381D1 (de) Betäubungsvorrichtung für Schlachttiere
FI864475A7 (fi) Bordetella-tautien varhaisdiagnoosimenetelmä ja tähän tarkoitettu kit ti.
FI883351A7 (fi) Diagnostinen menetelmä häiriöiden toteamiseksi RNA-aasi L:ssä
DE68911974D1 (de) Ophthalmologisches Diagnose-Verfahren und Gerät.
BR7807559A (pt) Processo e aparelho para a determinacao das condicoes bioenergeticas no homen ou animal no ambito da diagnose por acupuntura
FI882122A7 (fi) In vitro -diagnostinen menetelmä periodontaalisten sairauksien toteamiseksi

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application